Cell Microarray Technology

Physiological system for detecting ligand-receptor interactions

Retrogenix’s unique cell microarray technology provides a fast, accurate and effective solution for discovering the human cell surface and secreted protein targets of antibodies, proteins, viruses and small molecules. This allows our global pharmaceutical clients to:

  • overcome the critical deconvolution step in phenotypic drug discovery
  • uncover novel, high quality and exploitable drug targets
  • explore safety liabilities of lead candidates using the most comprehensive human expressed off-target system

Retrogenix’s biologically-relevant system detects specific interactions with a high degree of sensitivity. This unique tool uses proprietary arrays of expression vectors – encoding over 5,900 full-length human plasma membrane and tethered secreted proteins – spotted onto slides. Human cells grown over the top become reverse-transfected resulting in cell surface expression of each respective protein at distinct slide locations. The test molecule is applied and specific binding analysed and confirmed using an appropriate detection system.


Technology Advantages

Retrogenix’s broad coverage extends across the full spectrum of known plasma membrane and secreted protein sub-classes including, amongst others: G protein coupled receptors (GPCRs), ion channels, drug transporters, Ig superfamily receptors, cytokines, hormones, immunomodulatory molecules, enzymes and growth factor receptors.

Keep reading to find out how our cell microarray technology compares to standard methods:

Keep reading

Case Studies

Retrogenix’s results are now supporting patent applications, appearing in peer-reviewed publications and being presented at international conferences. Our case studies highlight a selection of these projects providing further details on receptor identification, target deconvolution and specificity screening for biotherapeutics such as CAR T cells and antibodies.

Find out about how the Retrogenix Technology has been used:

Case Studies

The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
Capella Bioscience Logo
Sanofi Logo
Unum Theraputics Logo
Celyad Logo
Retrogenix helped us to crack a very challenging problem, the result of which has significantly advanced our research. A collaborative approach, alongside an in-depth scientific and technical knowledge of their technology turned an unsuccessful initial screen into an extremely successful secondary screen. We have already committed to further studies.
Dr. Nicky Cooper, CSO, Peptinnovate